Oncology-focused biotechnology firm BlossomHill Therapeutics Inc. raises $150 million in an upsized initial public offering on August 7, 2026. Although the company prices its IPO at $16 per share, marketing 7.8 million shares within a $15 to $17 range, its stock opens below that mark at $15.75 in New York. BlossomHill shares ultimately decline by 1.6% during their market debut, reflecting immediate post-IPO trading pressure.
BlossomHill Therapeutics IPO
- ▪BlossomHill Therapeutics Inc. is an oncology-focused biotechnology firm that launched its initial public offering on August 7, 2026
- ▪BlossomHill Therapeutics Inc. raised $150 million in an upsized United States initial public offering on August 7, 2026
Post-IPO stock performance
- ▪BlossomHill Therapeutics Inc. shares fell 1.6% during their trading debut in New York on August 7, 2026
- ▪BlossomHill Therapeutics Inc. stock opened at $15.75 on August 7, 2026, which was below its initial public offering price
IPO pricing details
- ▪BlossomHill Therapeutics Inc. priced its initial public offering at $16 per share
- ▪BlossomHill Therapeutics Inc. marketed 7.8 million shares within an estimated price range of $15 to $17 each
Story comments
Loading comments…